Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance
Related Posts
Mirjalili SR, Atlas K, Reeves AP, Zhang C, Wasserthal J, Azimi A, Hashemi A, Mozafarybazargany M, Ghaffari Jolfayi A, Atlas T, Henschke CI, Yankelevitz DF,[...]
Tullis B, Nicolas L, Alt JA, Bodner TE, Chang M, Chowdhury NI, Chung S, Eshaghian P, Gao YA, Getz A, Gill AS, Hwang PH, Khanwalkar[...]
Degobbi T Q S Lopes F, Vieira RP, Abbasi A. Editorial: The experimental models as a tool for studying therapeutic targets in COPD: lessons learned.[...]